Trials / Completed
CompletedNCT00282659
The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Hartford Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if magnesium can improve blood pressure, cholesterol, and blood sugar control in patients with implantable cardioverter defibrillators (ICDs).
Detailed description
Magnesium is the second most abundant intracellular cation and plays a vital role in many physiologic processes. It has been determined that patients with cardiovascular disease have intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with CAD have risk factors that lead to the development and or propagation of atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and diabetes. Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they have on cholesterol, blood pressure, and blood glucose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | magnesium L-lactate |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-01-27
- Last updated
- 2019-05-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00282659. Inclusion in this directory is not an endorsement.